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ABSTRACT 
 
Obesity and type 2 diabetes mellitus are parallel global pandemics fueled 
by worldwide trends toward longer lifespan, Western high-fat diet, and sedentary 
lifestyle. Lipotoxicity – lipid overflow from adipose tissue to liver, muscle, and 
pancreas resulting from chronically elevated plasma free fatty acid levels – is 
now known to be the underlying cause of insulin resistance and T2DM. Control of 
lipolysis in adipose tissue is central to the regulation of plasma free fatty acid. 
Adipose triglyceride lipase (ATGL), the rate-limiting lipolytic enzyme in adipose 
tissue, is downregulated in the insulin-stimulated state, and this antilipolytic 
signal is defective in obesity and T2DM and may contribute to lipotoxicity. The 
antilipolytic insulin signal is mediated by mammalian target of rapamycin complex 
1 (mTORC1), but how activated mTORC1 decreased ATGL expression remained 
elusive. The Kandror Lab recently identified transcription factor early growth 
responsive gene 1 (Egr1) as the missing link between insulin-activated mTORC1 
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and decreased ATGL expression. mTORC1 induces Egr1, which directly binds 
the ATGL promoter and decreases its expression.  
Intriguingly, Egr1 has also been implicated in a new model of the 
pathogenesis of insulin resistance in the pre-diabetic hyperinsulinemic state. 
Several groups have demonstrated that chronic hyperinsulinism causes an 
imbalance between PI3K/Akt signaling and MAPK signaling, and this defect is 
mediated by high levels of Egr1 in obesity. Additionally, the endocannabinoid 
system (ECS) is known to be hyperactive in obesity and diabetes, and 
antagonism of cannabinoid receptor 1 (CB1) by pharmaceutical rimonabant was 
effective at decreasing weight and improving insulin resistance in overweight and 
obese patients. Previous research demonstrated induction of Egr1 by CB1 
stimulation in neurons, however the same effect has not been demonstrated in 
adipocytes. 
We stimulated murine 3T3-L1 and human adipocytes with 2 uM 
arachidonyl-2’-chloroethylamide (ACEA), a synthetic analogue of major 
endocannabinoid anandamide and a specific CB1 agonist. Egr1 mRNA was 
significantly increased in ACEA-stimulated murine and human adipocytes relative 
to controls after 4 hours, as analyzed by quantitative polymerase chain reaction. 
This finding potentially implicates hyperactive ECS during obesity in the 
pathogenesis of insulin resistance, and it further validates CB1 as a rich diabetes 
drug target. 
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INTRODUCTION 
 
1. Obesity, Diabetes, and Public Health 
Obesity and Type 2 Diabetes Mellitus (T2DM) are twin global health 
pandemics  [1]. The two diseases are intricately and definitively linked, to the 
extent that the term “diabesity” has entered the popular media lexicon [2]. In the 
United States, 18.8 million people were living with diagnosed diabetes and 7 
million with undiagnosed diabetes in 2010, for a national diabetes prevalence of 
8.3 percent. An additional 79 million Americans in 2010 exhibited pre-diabetic 
signs such as elevated fasting glucose and hemoglobin A1c levels [3]. Figure 1 
demonstrates the dramatic increase in diabetes prevalence in the United States, 
especially since 1990 [4]. Globally, the number of people living with diabetes 
doubled between 1980 and 2008, from 153 million to 347 million [1]. Although 
approximately 70 percent of the increase is attributed to population growth and 
longer lifespan, a fundamental driver of the diabetes pandemic is increased 
prevalence of obesity secondary to Western diet, overeating, and sedentary 
lifestyle [1]. 
Complications of diabetes are numerous. Diabetes deteriorates the 
vasculature and increases risk of heart disease, heart attack, stroke, blindness, 
nephropathy, and neuropathy; poor perfusion of the lower extremities increases 
risk of ulcer, gangrene, and amputation of the foot [3]. Diabetes is currently the 
seventh leading cause of death in the United States, and of the 15 leading 
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causes of U.S. deaths, diabetes had the second-largest increase in death rate 
between 2010 and 2011 (3.4 percent) [5]. 
 
 
Figure 1. Diabetes prevalence in United States. Number and percentage of 
Americans living with diabetes has increased drastically in the past two decades. 
Figure taken from “Long-Term Trends in Diagnosed Diabetes”, Centers for 
Disease Control and Prevention, 2011 [4]. 
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2. Pathogenesis of Insulin Resistance and T2DM 
Both Type 1 and Type 2 Diabetes Mellitus manifest as impaired glucose 
tolerance and fasting hyperglycemia. T1DM is caused by insulin deficiency due 
to autoimmune destruction of the pancreatic β-cells, and T2DM is caused by 
insulin insensitivity and resistance in muscle, liver, and fat tissue. T1DM, formerly 
labeled “juvenile onset” and “insulin-dependent”, presents in early life, most 
commonly during adolescence, and patients are dependent on lifelong 
subcutaneous injection of insulin. T2DM, formerly labeled “adult onset” and “non-
insulin-dependent”, classically presents in older adults and geriatric patients and 
is strongly associated with overweight and obesity. However, the diabetes and 
obesity epidemic has lowered the average age of T2DM onset to middle 
adulthood and has recently expanded to the young adult and pediatric 
populations. T2DM accounts for approximately 95 percent of all adult diabetes 
cases [3]. The remainder of this paper specifically addresses T2DM. 
The term “diabetes mellitus” derives from Latin and Greek and means 
excessive urine with a honey-sweet taste, and the condition has been known 
since antiquity. In the 1880s, Oskar Minkowski documented sweetness in the 
urine of pancreatectomized dogs, concluding that the pancreas secretes a 
substance critical for the regulation of blood glucose [6]. After Dr. Frederick 
Banting isolated insulin from pancreatic β-cells in 1921, the concept of regulation 
of blood glucose by insulin was firmly established in medicine, and thereafter 
diabetes was viewed primarily as a disorder of carbohydrate metabolism [6]. In 
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his paradigm-shifting 1992 Science paper, Dr. John McGarry asked how diabetes 
research might be different if Minkowski had smelled acetone (a byproduct of 
ketoacids) in the urine rather than tasted sugar, and McGarry argued that the role 
of lipid metabolism dysregulation had been underappreciated in the pathogenesis 
of insulin resistance and diabetes [6]. 
Insulin resistance is now understood to arise primarily from defects in lipid 
metabolism [7]. Lipotoxicity, a term introduced by Unger and McGarry in 1994, is 
the aberrant accumulation of lipids in non-adipose tissue, particularly in liver, 
muscle, and pancreatic β-cell, following increased plasma free fatty acid (FFA) 
levels [8]. Unger proposed that increased plasma FFA had parallel effects of 
increasing insulin secretion (hyperinsulinemia) and increasing peripheral insulin 
resistance long before diagnosis of overt diabetes [9]. Dresner et al. 
demonstrated that elevated plasma FFA induced insulin resistance in humans by 
diminishing insulin signal transduction through the phosphatidylinositol 3-kinase 
(PI3K) pathway [10]. Elevated plasma FFA may represent caloric intake in 
excess of the triacylglycerol (TAG) storage capacity of adipose tissue; high FFA 
increases ectopic TAG accumulation and causes subsequent metabolic 
dysfunction of tissues such as muscle, liver, and pancreatic β-cell [11].  
Chronically elevated plasma FFA decreases insulin secretion by 
pancreatic β-cells [12], decreases insulin-stimulated glucose uptake by skeletal 
muscle [13], decreases insulin-stimulated suppression of hepatic glucose 
production (hGP) by gluconeogenesis [13], and decreases insulin-stimulated 
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suppression of lipolysis in adipose tissue [14]. All of these effects contribute to 
the “metabolic syndrome”, a state of hyperlipidemia, hypercholesterolemia, 
ectopic adiposity, insulin resistance, and hyperglycemia [15]. Therefore, precise 
regulation of plasma FFA concentration is vitally important to maintain normal 
metabolic function and prevent the pathogenesis of insulin resistance and 
diabetes mellitus. 
 
3. Lipolysis in Adipose Tissue 
Among the several contributors to increased plasma FFA levels in obesity 
and diabetes, dysregulated lipolysis in adipose tissue (AT) is central [16]. In 
normal physiology, the fasted state induces lipolysis in the adipocyte lipid droplet 
(LD) and release of FFA into circulation. FFA is then used by the liver and 
muscle for mitochondrial β-oxidation and by the liver for ketogenesis. The fed 
state suppresses lipolysis in AT and stimulates uptake of plasma glucose by 
muscle, liver, and AT. LDs are present in all cell types and occupy minor volume, 
approximately 1 micron, providing a small TAG and cholesteryl ester depot for 
use by individual cells. In white adipose tissue (WAT), LDs are approximately 50 
microns and occupy nearly the entire cell, providing TAG energy storage for the 
whole organism [17]. 
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3.1  Adipose Triglyceride Lipase 
Until 2004, the two major lipases characterized in AT were monoglyceride 
lipase (MGL) and hormone-sensitive lipase (HSL). HSL is selective for 
diacylglycerides (DAG) and catalyzes the hydrolysis of one of the two acyl 
groups on DAG, resulting in one FFA and one monoacylgyceride (MAG). HSL 
also has some TAG hydrolysis activity but has much higher affinity for DAG 
substrates. MGL is selective for MAG and catalyzes the hydrolysis of the final 
acyl group from glycerol, releasing one FFA and glycerol. Of these two lipases, 
HSL was viewed as the rate-limiting lipolytic enzyme in AT. Vaughan et al. wrote 
in 1964, “It seems reasonable to conclude that activation of the hormone-
sensitive lipase system accounts for wholly or in large part for the fat-mobilizing 
action of epinephrine, norepinephrine, ACTH, glucagon, and TSH [18].” In 2001, 
Haemmerle et al. showed HSL-null mice exhibited decreased lipolysis but 
accumulation of DAG and not TAG in AT, indicating the existence of a third 
lipase in AT specific for TAG conversion to DAG [19].  
Three groups reported the identification of adipose triglyceride lipase 
(ATGL) in 2004, an AT lipase selective for TAG hydrolysis to DAG [20] [21] [22]. 
Together, ATGL and HSL account for 95 percent of lipolysis in WAT [23]. ATGL 
is now known to be the rate-limiting enzyme in AT lipolysis [24]. Inactivation of 
ATGL in mice leads to dramatically increased adiposity throughout the body and 
causes premature death because of cardiac dysfunction [25]. These mice are 
also impaired in maintaining body temperature during cold as the availability of 
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plasma FFA for use in brown adipose tissue (BAT) thermogenesis is decreased 
[25]. As predicted by the lipotoxicity model, decreased plasma FFA in these mice 
increases insulin sensitivity and glucose tolerance [25]. In fact, ATGL-null mice 
are protected against high-fat diet (HFD) induced insulin resistance and glucose 
intolerance despite weight gain [26].  
Conversely, transgenic mice overexpressing ATGL are leaner with 
decreased TAG accumulation and smaller adipocytes secondary to increased 
lipolysis [27]. Intriguingly, these mice do not exhibit increased plasma FFA. 
Rather, genes for mitochondrial β-oxidation, peroxisomal α-oxidation, and 
thermogenesis are up-regulated in their adipocytes, including a 7-fold increase of 
uncoupling protein 1 (UCP1) and consequent higher body temperature [27]. 
These mice also show increased insulin sensitivity despite unchanged plasma 
FFA levels relative to control wild-type (WT) mice, indicating plasma FFA 
concentration is not the sole determinant of insulin sensitivity.  
 
3.2  Lipolysis Stimulation and Suppression 
The major stimulus for lipolysis in AT is activation of the β-adrenergic 
receptor (βAR) by catecholamines epinephrine and norepinephrine [28]. 
Stimulation of βAR, a G protein-coupled receptor (GPCR), activates adenylate 
cyclase, which catalyzes the conversion of adenosine monophosphate (AMP) to 
cyclic AMP (cAMP). Increased intracellular concentration of cAMP activates 
protein kinase A (PKA). Activated PKA induces lipolysis through several 
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effectors. PKA phosphorylates HSL, which activates the translocation of HSL to 
the LD where it can participate in lipolysis. PKA phosphorylates perilipin, a 
constituent “guardian protein” located at the LD-cytosol interface, leading to the 
release of CGI-58 from perilipin. CGI-58 is a co-activator of ATGL, and its 
release from phosphorylated perilipin increases ATGL activity 20-fold [29]. 
Tumor necrosis factor-α (TNF-α) also stimulates lipolysis, and the effect is 
mediated by G0S2 (G0/G1 switch gene 2), a selective inhibitor of ATGL [30]. 
TNF-α decreases transcription of G0S2, thus relieving ATGL of G0S2 inhibition 
and stimulating lipolysis. Glucocorticoids are also thought to stimulate lipolysis in 
AT, although this effect is somewhat ambiguous and its mechanism not 
definitively elucidated [31]. 
Recently, Sirtuin-1 (SIRT1), a protein deacetylase, was found to stimulate 
AT lipolysis [32]. SIRT1 is activated during fasting and deacetylates transcription 
factor forkhead box O1 (FoxO1), which can then directly bind the ATGL promoter 
and transactivate ATGL gene transcription. This effectively increases AT 
lipolysis. AMP-activated protein kinase (AMPK) has been implicated in 
stimulation of lipolysis, but Kandror et al. found no effect on lipolysis in a cell line 
with dominant-negative catalytic subunits of AMPK [32]. 
The major suppressor of lipolysis in AT is insulin [24]. The major mediator 
of insulin signal transduction is Akt, also called protein kinase B (PKB). Akt has 
myriad cellular targets, as shown in Figure 2 [33]. The three targets most relevant 
to insulin-stimulated suppression of AT lipolysis are tuberous sclerosis complex 2 
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(TSC2), FoxO1, and cyclic nucleotide phosphodiesterase-3b (PDE-3b) (not 
shown in Figure 2). Akt phosphorylates and activates PDE-3b, which catalyzes 
the conversion of cAMP to AMP, reversing the effect of catecholamine 
stimulation of βAR and suppressing lipolysis [34]. Akt phosphorylates the 
transcription factor FoxO1, which sequesters FoxO1 outside the nucleus, thus 
rendering it incapable of binding and activating the ATGL promoter [35]. Akt 
phosphorylates and inhibits TSC2, leading to the activation of mammalian target 
of rapamycin complex 1 (mTORC1) [36], a canonical signaling pathway 
discussed in the next section. Insulin also activates the canonical mitogen-
activated protein kinase (MAPK) pathway [37], the effects of which are discussed 
in later sections.  
A second suppressor of lipolysis in AT is adiponectin, an autocrine 
hormone secreted by AT. Adiponectin is viewed a “sensitizer” of insulin 
antilipolytic activity, but recent reports show adiponectin also inhibits lipolysis 
independent of insulin signaling [38]. High levels of the FFA palmitate decrease 
adiponectin expression and secretion and also induce lysosomal degradation of 
adiponectin [39]. 
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Figure 2. Phosphorylation targets of Akt.  Akt/PKB, the major effector of 
insulin signal transduction in AT, is a central mediator of myriad cellular 
processes. FoxO and TSC2 are especially relevant to insulin-stimulated 
suppression of lipolysis. FoxO – forkhead box O; TSC2 – tuberous sclerosis 
complex 2. Figure taken from Manning and Cantley, 2007. 
 
3.3  Insulin-PI3K-Akt-TSC2-mTOR Axis 
The activation of mTORC1 by insulin is a highly investigated insulin 
signaling pathway and is illustrated in Figure 3 [33]. Briefly, insulin binds insulin 
receptor (IR), a receptor tyrosine kinase (RTK), causing dimerization and 
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autophosphorylation of IR on tyrosine residues. IR recruits and phosphorylates 
insulin receptor substrate 1 (IRS1) on specific tyrosine residues. Phosphorylated 
IR and IRS1 recruit PI3K and Grb2 to the cell membrane and both IR and IRS1 
phosphorylate and activate PI3K and Grb2. Activated Grb2 (not shown in Figure 
3) activates the MAPK pathway [40]. Activated PI3K phosphorylates the 
membrane phospholipid PIP2, producing PIP3. Both Akt and phosphoinositide-
dependent kinase 1 (PDK1) are able to bind PIP3 via their pleckstrin homology 
(PH) domains. Akt is phosphorylated at Thr-308 by PDK1 and at Ser-473 by 
mTORC2. Both phosphorylation modifications are required for the full effector 
capabilities of Akt [41].  
Akt phosphorylates TSC2 at multiple residues suppressing its biological 
activity. TSC2 is a GTPase-activating protein (GAP) for the small GTP-bound 
protein Rheb (Ras homolog enriched in brain, a misnomer as Rheb is found in 
non-brain tissue such as AT). Rheb directly stimulates mTORC1. Therefore, 
activated Akt stimulates mTORC1 by inhibiting an inhibitor (TSC2) of Rheb. 
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Figure 3. Insulin activates mTORC1 via PI3K/Akt. Solid lines represent direct 
interaction and dotted lines represent indirect effects with unillustrated mediators. 
RTK – receptor tyrosine kinase; PI3K – phosphatidylinositol 3-kinase; PIP3 – 
phosphatidylinositol (3,4,5)-triphosphate; TSC2 – tuberous sclerosis complex 2; 
Rheb – ras homolog enriched in brain; mTOR – mammalian target of rapamycin; 
PDK1 – phosphoinositide-dependent kinase 1; PTEN – phosphatase and tensin 
homolog; IRS1 – insulin receptor substrate 1; S6K1 – ribosomal S6 protein 
kinase 1; 4EBP1 – eukaryotic initiation factor (eIF) 4E binding protein. Figure 
taken from Manning and Cantley, 2007. 
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Although many interesting details about the PI3K-Akt-TSC2-mTOR 
pathway are beyond the scope of this paper, several aspects require emphasis. 
Firstly, embedded in the pathway is a negative feedback signal. mTORC1 
phosphorylates and activates ribosomal protein S6 kinase 1 (S6K1), which in turn 
phosphorylates several substrates, including IRS1 [42]. This modification of IRS1 
at multiple serine residues decreases IRS1 binding to IR, decreases PI3K 
activation, and decreases the overall PI3K-Akt signal. Foster et al. hypothesized 
that overactive mTORC1 secondary to hyperinsulinemia in obesity decreases 
PI3K-Akt signaling through the S6K1-IRS1 mechanism and contributes to insulin 
resistance [41].  
Secondly, insulin also activates the MAPK signal cascade (not shown in 
Figure 3), and the MAPK pathway also activates mTORC1 [37], which will be 
important for the later discussion about transcription factor early growth 
responsive gene 1 (Egr1).  
Thirdly, and to the earlier point about insulin-stimulated suppression of 
lipolysis in AT, insulin decreases transcription of ATGL in an mTORC1-
dependent manner [36]. Constitutive activation of mTORC1 via insertion of a 
Rheb transgene decreases transcription of ATGL, suppresses lipolysis, and 
increases intracellular TAG. Similarly, TSC2-null mouse embryonic fibroblasts 
(MEFs), which exhibit overactive mTORC1, also show decreased transcription of 
ATGL and suppression of lipolysis. Conversely, inhibition of mTORC1 by 
rapamycin induces ATGL transcription and increases lipolysis [36]. The 
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transcription factor through which mTORC1 down regulates ATGL expression 
has been identified as Egr1 by the Kandror Lab, although the paper has yet to be 
published. 
 
3.4  Post-Translational Regulation of ATGL 
Because ATGL is the rate-limiting lipolytic enzyme in AT, and because AT 
lipolysis is a central contributor to plasma FFA levels, ATGL regulation is of keen 
importance in diabetes research. As discussed earlier, ATGL activity is inhibited 
by direct interaction with G0S2, a protein most highly expressed in AT and liver 
[28]. Knockdown of G0S2 increases both basal and βAR-stimulated lipolysis, and 
overexpression of G0S2 decreases lipolysis [30]. Recently, Schweiger et al. 
confirmed G0S2 interaction with and inhibition of ATGL in human adipocytes 
[43]. Also discussed earlier was CGI-58, a protein activator of ATGL. CGI-58 
directly interacts with ATGL and is required for the full activation of ATGL. 
Mutations in CGI-58 cause Chanarin-Dorfman Syndrome, which is characterized 
by excessive TAG accumulation in multiple tissues [29]. 
AMPK phosphorylates ATGL at Ser-406, which increases ATGL activity. 
However, different groups have shown AMPK activation to increase, decrease, or 
have no effect on lipolysis [32]. Unlike HSL, ATGL is not phosphorylated by PKA 
or MAPK [28]. 
Another possible regulator of ATGL at the protein level is the insulin-
stimulated degradation of ATGL by ubiquitination and selective autophagy. 
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Activated IRS1 is known to bind the Src homology 2 (SH2) domain of p62, an 
adaptor protein involved in joining ubiquitinated proteins with autolysosomal 
proteins [40]. Furthermore, some preliminary data from the Kandror Lab suggests 
that ATGL interacts with parkin, an E3 ubiquitin ligase, upon insulin stimulation. 
However, the role of autophagy in ATGL regulation is not clear. 
 
3.5  Transcriptional Regulation of ATGL 
Three transcription factors bind to and activate the ATGL gene promoter: 
IRF4, FoxO1, and PPARγ. Recently, Kandror et al. identified Egr1 as a fourth 
transcription factor that binds the ATGL promoter but has an inhibitory effect on 
ATGL expression. Data supporting this claim are under review for publication. 
 
a. Egr1 
Egr1 binds the ATGL promoter and decreases ATGL expression. Kandror 
et al. found that Egr1 is the mediator of mTORC1 suppression of ATGL 
transcription in the insulin-stimulated state (unpublished data). WT MEFs and 
TSC2-null MEFs were transfected with luciferase cDNA linked to ATGL promoter. 
In TSC2-null MEFs, mTORC1 was hyperactivated, and luciferase expression 
was decreased significantly relative to WT MEFs, supporting the previous finding 
that insulin-activated mTORC1 decreases ATGL expression. Rapamycin 
treatment of yeast inhibited mTORC1 and increased ATGL mRNA. A yeast 
genetic screen identified Msn4 as a transcription factor that suppresses ATGL 
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gene transcription. The mammalian homologue for Msn4 is Egr1, also called 
Krox24. Co-transfection of ATGL promoter-linked luciferase cDNA and Egr1 
cDNA in HEK-293T cells significantly decreased luciferase expression relative to 
empty vector. 
During a time course study of mRNA and protein levels of ATGL and Egr1 
in 3T3-L1 adipocytes, Kandror et al. found that Egr1 mRNA levels increased 
dramatically after 4 hours of insulin stimulation (Figure 4). After 8 hours of insulin, 
Egr1 mRNA was lower than at 4 hours but Egr1 protein levels were increased 
significantly. At 8 hours, there was no change in ATGL protein level but 
significantly decreased ATGL mRNA. By 16 hours of insulin stimulation, Egr1 
mRNA and protein levels returned to baseline, ATGL mRNA levels similar were 
to the 8-hour time point, but ATGL protein was significantly decreased. This 
study demonstrates that suppression of ATGL protein is subsequent to induction 
of Egr1 in the insulin-stimulated state. Chromatin immunoprecipitation (ChIP) 
verified the direct binding of Egr1 protein to ATGL promoter. Rapamycin, the 
mTORC1 inhibitor, blocked insulin-induced Egr1 expression and rescued ATGL 
from insulin-stimulated down-regulation. 
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Figure 4. ATGL and Egr1 expression during insulin time course. 3T3-L1 
adipocytes treated with 100 nM insulin for the time periods shown. Levels of 
ATGL and Egr1 mRNA measured in triplicate by quantiative PCR and normalized 
by 36B4 mRNA. Levels of ATGL and Egr1 protein measured by Western blot 
with actin as loading control. ATGL – adipose triglyceride lipase; Egr1 – early 
growth responsive gene 1. Figure taken from unpublished Kandror et al data. 
 
 
b. IRF4, FoxO1, PPARγ 
Interferon regulatory factor 4 (IRF4) binds the ATGL promoter and 
transactivates the ATGL gene, and insulin signaling inhibits IRF4 transactivation 
of ATGL [44]. The ATGL promoter also contains two canonical FoxO1 binding 
sites, and Kandror et al. demonstrated that co-transfection of FoxO1 and 
 18 
luciferase gene with ATGL promoter led to expression of luciferase [35]. 
Knockdown of FoxO1 in 3T3-L1 adipocytes decreased ATGL expression, basal 
lipolysis, and βAR-stimulated lipolysis. Conversely, transfection of MEFs with 
FoxO1-containing lentivirus increased ATGL expression. SIRT1, which is active 
during fasting, deacetylates and activates FoxO1, leading to increased ATGL 
expression and lipolysis [32]. Insulin-stimulated Akt phosphorylates FoxO1, thus 
excluding FoxO1 from the nucleus and inhibiting its ATGL promoting activity [35]. 
The peroxisome proliferator-activated receptor γ (PPARγ) transactivates 
ATGL gene expression by binding the ATGL promoter [45]. The PPAR family 
contains 4 members that are nuclear receptor transcription factors whose ligands 
include fatty acids, acyl-CoAs, glycerol phospholipids, and eicosanoids [28]. 
PPARγ is expressed most highly in WAT. PPARγ agonists such as rosiglitazone 
and the thiazolidinedione (TZD) anti-diabetic drugs increase ATGL mRNA and 
protein, and this effect is demolished by antagonism or siRNA knockdown of 
PPARγ [46].  
 
4. PI3K/Akt and MAPK Signaling Imbalance in Insulin Resistance 
As discussed previously, insulin activates both the PI3K/Akt and MAPK 
signal cascades in AT. Both Akt and MAPK – also called extracellular signal-
regulated kinase (ERK) – phosphorylate and inhibit TSC2, leading to the 
activation of mTORC1 [47] and increased expression of Egr1. Egr1 expression is 
increased in ob/ob mice and in the AT of diabetic patients [37]. Concordant with 
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this observation, obese patients and T2DM patients exhibit decreased 
expression of ATGL, as do the mouse models of obesity (ob/ob mice) and 
diabetes (db/db mice) [48].  
Shen et al. present a model that depicts the role of elevated Egr1 in the 
development of imbalance between PI3K/Akt and MAPK signaling [37]. Chronic 
hyperinsulinemia, as experienced by pre-diabetic patients, leads to chronically 
elevated Egr1 levels in AT. Egr1 transactivates the gene for geranyl geranyl 
pyrophosphate synthase (GGPPS), which catalyzes the synthesis of 20-carbon 
quadruple isoprene molecule called geranyl geranyl pyrophosphate (GGPP). GG 
is a prenylation (anchoring) moiety added to Ras, the small GTPase, to increase 
cell membrane anchoring and thus enhance MAPK signaling as shown in Figure 
5. Concurrently, activated ERK phosphorylates IRS1 at Ser-612, which 
diminishes insulin signal transduction through the PI3K/Akt pathway. Chronic 
hyperinsulinemia therefore increases MAPK signaling but decreases PI3K/Akt 
insulin signaling in an Egr1-dependent mechanism. Shen et al. demonstrated 
that insulin sensitivity could be restored in previously insulin-resistant adipocytes 
by any of the following: 1) Egr1 ablation; 2) GGPPS knockdown; 3) ERK 
inhibition [37]. 
In addition to the Egr1-GGPPS mechanism of PI3K/Akt – MAPK 
imbalance in pre-diabetic hyperinsulinemia, Xiao et al. introduced a second 
mechanism [49]. Egr1 also transactivates the phosphatase and tensin 
homologue (PTEN) gene, whose protein product dephosphorylates PIP3 and 
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inhibits PI3K/Akt signal transduction. As above, pre-diabetic hyperinsulinism 
increases Egr1 expression in AT, which increases MAPK signaling via the 
GGPPS-Ras mechanism and decrease PI3K/Akt signaling via IRS1 
phosphorylation and PTEN induction. Furthermore, Sartipy et al. found that Egr1 
is one of a few genes that remain insulin-sensitive during the development of 
adipocyte insulin resistance [50]. Thus, Egr1 is emerging as a critical mediator in 
the development of insulin resistance and T2DM. 
 
Figure 5. PI3K/Akt – MAPK imbalance in hyperinsulinemia. GGPPS – geranyl 
geranyl pyrophosphate synthase; PI3K – phosphatidylinositol 3-kinase; Egr1 – 
early growth response gene 1; Erk – extracellular signal-regulated kinase; IRS1 – 
insulin receptor substrate 1; GGTase – geranyl geranyl transferase. Figure taken 
from Shen, et al. 2011. 
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5. Endocannabinoid System 
The endocannabinoid system (ECS), as its name hints, was first 
investigated in relation to the psychotropic effects of the smoking plant Cannabis 
sativa, or marijuana. The psychoactive compound in marijuana, Δ9-
tetrahydrocannabinol (Δ9-THC), binds cannabinoid receptors in the brain to 
produce euphoria and stimulate appetite, among other effects. The ECS has 
become a major diabetes research topic because ECS is hyperactive in obesity 
and T2DM, and pharmacologic blockade of the ECS has been shown to improve 
insulin resistance and overall lipid metabolism in mouse and human trials [51]. 
 
5.1 Cannabinoid Receptors 
Cannabinoid receptors are classical 7-transmembrane GPCRs, and there 
are two subtypes: CB1 and CB2. CB1 was traditionally labeled the “brain type”, 
but current research has found CB1 expression in a large variety of tissues 
including AT. CB2 is only expressed in immunity and inflammatory cells, with the 
exception of keratinocytes [52]. Among the multiple downstream effectors of CB1 
activation, a major one is ERK [53]. 
 
5.2 Agonists and Antagonists 
Endocannabinoids are endogenous agonists of cannabinoid receptors. 
The first endocannabinoid to be identified was N-arachidonyl ethanolamine 
(AEA) in 1992 [52], followed later by identification of 2-arachidonyl glycerol (2-
AG). AEA, also called anandamide from the Sanskrit meaning “bliss”, and 2-AG 
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are the two most important endocannabinoids, although others have been 
identified as shown in Figure 6. All of these molecules contain a 20-carbon 
arachidonyl moiety derived from arachidonic acid [54]. 
HU210 is a synthetic analogue to Δ9-THC and is the most potent CB1 
agonist currently available [52]. CP-55940 is also a synthetic Δ9-THC mimetic 
and CB1 agonist. Arachidonyl-2’-chloroethylamide (ACEA) is a synthetic 
analogue to AEA and a selective CB1 agonist. SR141716A is a synthetic 
selective CB1 antagonist. The generic drug name for SR141716A is rimonabant.  
Natural Δ9-THC and the synthetic molecules are illustrated in Figure 7. 
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Figure 6. Structures of endocannabinoids. The two most important 
endocannabinoids are anandamide, also called N-arachidonyl ethanolamine 
(AEA), and 2-arachidonyl glycerol (2-AG). Figure taken from Piomelli, 2003. 
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Figure 7. Structures of exogenous cannabinoids. A) Plant (Δ9-THC) and 
synthetic (HU-210 and CP-55940) nonselective cannabinoid agonists. B) 
Synthetic selective CB1 antagonist SR141716A (generic drug rimonabant) and 
synthetic selective CB2 antagonist SR144528. C) Synthetic selective CB1 
agonist ACEA and synthetic selective CB2 agonist AM1241. Δ9-THC – Δ9-
tetrahydrocannabinol; ACEA – arachidonyl-2’-chloroethylamide. Figure taken 
from Piomelli, 2003. 
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5.3 Rimonabant 
Rimonabant, a selective CB1 antagonist, was approved and marketed in 
Europe from 2006 to 2009 for indication of obesity [55]. The U.S. Food and Drug 
Administration (FDA) did not approve the drug because of adverse psychiatric 
effects including anxiety, depression, and suicidal ideation. Rimonabant was 
withdrawn from the European market in 2009 for the same reasons. 
Notwithstanding the psychiatric side effects, rimonabant was an effective drug. 
Rimonabant caused weight loss, decreased waist circumference, improved TAG 
and cholesterol levels, improved insulin sensitivity and glucose tolerance, and 
increased adiponectin levels [56]. 
 
5.4 Egr1 
Several groups have demonstrated Egr1 induction by CB1 agonists in 
non-adipose tissue. Boueboula et al. showed CB1 agonism by CP-55940 
induced expression of Egr1 in human astrocytes [57]. Graham et al. showed CB1 
agonism by HU210 induced Egr1 in an ERK-dependent manner in neuro2A 
neuronal cells [53]. Conversely, the same cells treated with CB1 antagonist 
SR141716A had decreased Egr1 expression. This finding raises the question of 
whether rimonabant’s effects of improved insulin sensitivity and weight loss could 
be attributed, in part, to suppression of Egr1.  
The mechanisms through which CB1 agonism and antagonism effect 
whole body metabolism are difficult to elucidate because CB1 is expressed both 
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centrally (in brain) and peripherally (in AT, liver, and muscle). Cota et al. 
demonstrated that age affects the extent to which central or peripheral CB1 
controls metabolic state. They found that young CB1-null mice were lean 
secondary to reduced caloric intake, an effect mediated by the hypothalamus and 
other brain regions. Adult CB1-null mice were lean secondary to peripheral 
metabolic changes such as reduced lipogenesis in AT [58]. Trillou et al. found 
that compared to WT mice, CB1-null mice had 24 percent lower body weight and 
60 percent lower adiposity on a normal diet at week 20 [59]. Furthermore, they 
found that high fat diet (HFD)-induced obesity does not occur in CB1-null mice. 
Again, these results are attributable to both central effects (decreased appetite 
and food intake in CB1-null mice) and peripheral effects (decreased adiposity). 
The extent to which CB1 induction of Egr1 contributes to these peripheral effects 
requires further investigation. 
 
6. Thesis Objective 
Obesity and Type 2 Diabetes Mellitus are interlinked global health 
pandemics that demand exhaustive research. In the past two decades, the field 
has undergone a paradigm shift from framing diabetes as primarily a 
carbohydrate metabolism disorder to primarily a lipid metabolism disorder with 
secondary sugar consequences. The progression from mild insulin resistance to 
overt diabetes is now understood to involve dysregulation of plasma free fatty 
acid levels prior to glucose intolerance or hyperglycemia. This is the so-called 
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“lipotoxicity” model of insulin resistance. The Kandror Lab investigates the 
molecular mechanisms through which insulin suppresses lipolysis in adipose 
tissue, a fundamental signaling pathway that is defective in obesity and T2DM. 
Recent work by the Kandror Lab has revealed mammalian target of 
rapamycin complex 1 (mTORC1) as a mediator of insulin’s antilipolytic effect in 
adipose tissue. Moreover, the lab has identified the transcription factor Egr1 as 
the mediator of mTORC1’s downregulation of adipose triglyceride lipase (ATGL), 
the rate-limiting lipolytic enzyme in adipose tissue. Several recent models 
illustrate how chronic hyperinsulinism in the pre-diabetic state leads to imbalance 
between PI3K-Akt and MAPK signal cascades in adipose tissue and results in 
adipose insulin resistance. These models are based on increased Egr1 
expression in obesity. 
Other groups have shown Egr1 to be a downstream effector of 
cannabinoid receptor 1 (CB1) in neurons. CB1 is also expressed in adipose 
tissue and is known to contribute to metabolic homeostasis. The 
endocannabinoid system is hyperactive in obesity and T2DM, and pharmacologic 
blockade of CB1 by the drug rimonabant was effective at weight loss, improving 
insulin sensitivity, and improving overall lipid metabolism. The specific goal of this 
project was to demonstrate for the first time that CB1 agonism induces Egr1 in 
adipocytes. Further investigation will be required to determine how CB1 agonism 
affects ATGL expression and lipolysis in adipose tissue.  
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MATERIALS AND METHODS 
 
3T3-L1 Adipocyte Differentiation 
Murine 3T3-L1 preadipocytes cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) with 4.5 g/L glucose, L-glutamine, and sodium pyruvate 
(Cellgro 10-013-CV) supplemented with 10% donor bovine serum (Atlanta 
Biologicals S11350) and 1% penicillin-streptomycin-L-glutamine (Cellgro 30-009-
Cl). Cells incubated at 37°C and 10% CO2. Media replaced every 2-3 days. 
At 2 days post-confluence (Day 0), media replaced with MDI induction 
media prepared as follows: DMEM with 4.5 g/L glucose, L-glutamine, and sodium 
pyruvate (Cellgro 10-013-CV) supplemented with 10% fetal bovine serum (Gibco 
10437-028), 0.5 mM 3-isobutyl-1-methylxanthine (Sigma I-7018), 1 uM 
dexamethasone (Sigma D-4902), and 0.17 uM insulin (Sigma I-5500). At days 2, 
4, and 6, media replaced with maintenance media (DMEM with 10% FBS). Cells 
incubated at 37°C and 10% CO2.  
 
Human Adipocyte Differentiation 
Human adipocytes procured from subcutaneous adipose tissue were 
generously gifted by Mi-Jeong Lee, PhD, of the Fried Laboratory at Boston 
University School of Medicine. The adipocytes were received on Day 12 of 
differentiation in the following media: DMEM-F12 (Invitrogen 12500-062) with 
17.5 mM glucose, 0.5 mM sodium pyruvate, and 2.5 mM L-glutamine, 
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supplemented with 100 units/ml penicillin-streptomycin, 25 mM sodium 
bicarbonate, 15 mM HEPES, 33 uM biotin, 17 uM pantothenic acid, 10 nM 
insulin, and 10 nM dexamethasone. Media was serum-free. Cells incubated at 
37°C and 5% CO2. 
 
Arachidonyl-2’-chloroethylamide (ACEA) Stimulation 
Murine 3T3-L1 adipocytes and human adipocytes were stimulated with 2 
uM ACEA (Cayman 91054). ACEA, molecular weight 366 g/mol, was received as 
5 mg dissolved in 500 ul methyl acetate. To 250 ul of the reagent, 250 ul dimethyl 
sulfoxide (American Bioanalytical AB0-3091) was added to create solution of 2.5 
mg ACEA dissolved in 500 ul of 50% methyl acetate and 50% DMSO. To each of 
five 100 ul aliquots of this solution, 400 ul DMSO was added, to create solutions 
of 0.5 mg ACEA dissolved in 500 ul of 10% methyl acetate and 90% DMSO, for a 
final concentration of 2.73 mM ACEA. To stimulate adipocytes with 2 uM ACEA, 
3.66 ul of 2.73 mM stock ACEA was added to cell culture dishes with 5 ml media. 
Murine 3T3-L1 adipocytes were serum-starved for 3 hours prior to ACEA 
stimulation. Human adipocytes were insulin- and dexamethasone-starved for 3 
hours prior to ACEA stimulation. 
 
Insulin Stimulation 
Murine 3T3-L1 adipocytes were stimulated with 100 nM insulin from 
bovine pancreas (Sigma I-5500), molecular weight 5733 g/mol. Insulin powder 
was dissolved in 0.02 M HCl to concentration 1 mg/ml, or 170 uM. To stimulate 
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adipocytes with 100 nM insulin, 3 ul of 170 uM stock insulin was added to cell 
culture dishes with 5 ml media. Cells were serum-starved for 3 hours prior to 
insulin stimulation. 
 
Humulin Stimulation 
Human adipocytes were stimulated with 100 nM humulin (borrowed from 
Mi-Jeong Lee, PhD, of the Fried Laboratory at Boston University School of 
Medicine). Humulin was received as 60 uM stock solution. To stimulate 
adipocytes with 100 nM humulin, 8.3 ul of 60 uM stock humulin was added to cell 
culture dishes with 5 ml media. Cells were insulin- and dexamethasone-starved 
for 3 hours prior to humulin stimulation. 
 
Western Blot Analysis of ATGL and Egr1 in Murine 3T3-L1 Adipocytes and 
Human Adipocytes 
Cells washed on culture dishes twice with 1X phosphate-buffered saline 
and placed on ice. Cells collected with cold lysis buffer (20 mM Tris-HCl at pH 
7.4, 120 mM NaCl, 1% triton, 1 mM EGTA) supplemented with 1:100 protease 
inhibitor cocktail (Sigma P-8340) and 1:100 phosphatase inhibitor cocktail (Sigma 
P-0044). Cell lysates stored at -20°C. Cell lysate total protein concentration for 
Western blot analysis measured using a BCA assay kit (Thermo Scientific 23228 
and 23224).  
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Proteins were prepared for SDS-polyacrylamide gel electrophoresis by 
mixing 15 ug total protein per well with additional lysis buffer to total volume of 20 
ul per well. Each well sample received 5 ul 5X laemmli sample buffer 
(supplemented with 1:3 β-mercaptoethanol), and all well samples were boiled at 
95°C for 5 minutes prior to gel loading. ColorPlus prestained protein ladder (New 
England Biolabs P-7711S) was used as molecular weight marker. 
Proteins were separated on 8% polyacrylamide gels prepared with 30% 
ProtoGel (National Diagnostics EC-890) and transferred to Immobilon-P 
Membranes (Millipore Corp. IPVH00010) in transfer buffer (25 mM Tris, 192 mM 
glycine) at 4°C. Following transfer, the membranes were washed three times in 
1X PBS-Tween 20 (PBST) and blocked with 10% BSA in PBS with 0.5% Tween 
20 for 1 hour. After three washes with PBST, blots were probed overnight with 
specific primary antibodies at 4°C. Primary antibodies: rabbit anti-ATGL (Cell 
Signal 2138), rabbit anti-Egr1 (Santa Cruz Biotechnology sc-110). After wash 
three times with PBST, blots incubated with horseradish peroxidase-conjugated 
secondary antibodies for 1 hour, and washed three times with PBST. Secondary 
antibodies: goat anti-rabbit IgG (Thermo Scientific 31460), goat anti-mouse IgG 
(Thermo Scientific 31430).  
Protein bands were detected with the Western Lightning Plus-ECL 
Enhanced Chemiluminescence Substrate kit (PerkinElmer NEL104001EA) using 
the Bio-Rad Universal Hood II Gel Imager and corresponding software ImageLab 
Version 4.1. 
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RNA Extraction After Stimulation of Adipocytes 
RNA extracted from 3T3-L1 adipocytes and human adipocytes after 
stimulation by insulin, humulin, ACEA, or no stimulation. TRIzol reagent 
(Invitrogen 15596-026) added to plates to collect cell lysate, followed by addition 
of chloroform. After vigorous shaking and centrifugation at 12,000g for 15 min, 
top aqueous phase containing nucleic acid harvested and added to 2 volumes of 
isopropylalcohol. After vigorous shaking and centrifugation at 12,000g for 10 min, 
supernatant discarded and nucleic acid pellet washed with 75% ethanol, 
vortexed, centrifuged at 7,500g for 5 min, and air-dried 10 min. Pellet dissolved in 
20 ul RNase-free water (distilled, autoclaved water with 0.1% 
diethylpyrocarbonate). RNA concentration measured using spectrophotometer. 
RNA samples treated with DNase. To 10 ug RNA, final volume brought to 
85 ul with DEPC-water. To each, 10 ul 10X DNase buffer (Invitrogen AM8170G) 
and 5 ul DNase I (Invitrogen AM2224) was added, and samples incubated at 
37°C for 40 min. Following incubation, 200 ul DEPC-water and 300 ul phenol 
added, vortexed, and centrifuged. Upper aqueous layer containing RNA 
collected, 25 ul sodium acetate and 625 ul ethanol added, and samples stored 
overnight at -20°C. Samples centrifuged 15 min, supernatant removed, pellet 
washed with 75% ethanol, vortexed, centrifuged, supernatant removed, and air-
dried 10 min. Finally, RNA pellet dissolved in 20 ul DEPC-water and stored at -
70°C. 
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Reverse Transcription of RNA to cDNA 
Total RNA concentration measured using spectrophotometer. To 1 ug 
total RNA, DEPC-water added to volume of 10 ul, and 2 ul random decamers 
added. Samples heated to 80°C for 3 min on thermal cycler (MWG AG Biotech 
Primus 96 Plus). The remaining reverse transcription components added 
according to RETROScript kit (Ambion AM1710). Samples incubated on thermal 
cycler at 44°C for 1 hour, followed by 10 min incubation at 92°C to inactivate 
reverse transcriptase. Reaction tubes were 0.2 ml polypropylene PCR 8-tubes 
with clear caps (USA Scientific 1402-1900). 
 
Analysis of mRNA Expression Using Quantitative Polymerase Chain 
Reaction 
Reaction components for qPCR mixed according to Brilliant II SYBR 
Green QPCR Master Mix (Agilent Technologies 410024). Briefly, 0.5 ul template 
cDNA added to 12.5 ul SYBR Green PCR Master Mix and 7 ul distilled water. 
Reaction tubes were Mx4000 8-tube strips and caps (Agilent Technologies 
410022 and 410024). 5 ul primer mixture (3 ul forward and 3 ul reverse added to 
94 ul distilled water) was added to each tube. Primers were as follows: mouse 
Egr1, forward 5’-CCACAACAACAGGGAGACCT-3’ and reverse 5’-
ACTGAGTGGCGAAGGCTTTA-3’; human Egr1, forward 5’-
CCGCAGAGTCTTTTCCTGAC-3’ and reverse 5’-
TGGGTTGGTCATGCTCACTA-3’ (Eurofins MWG Operon). All samples prepared 
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in triplicate. mRNA expression levels normalized to GAPDH mRNA in the murine 
3T3-L1 adipocyte triplicate samples and to RPS18 mRNA in the human 
adipocyte triplicate samples. Primers for RPS18 mRNA (NM 022551.2) 
generously donated by Yasuo Ido, MD, PhD, of the Ruderman Laboratory at 
Boston University School of Medicine. Reactions were run at 95°C for 2 minutes 
followed by 30 cycles of 95°C for 2 minutes, 58°C for 30 seconds, and 72°C for 1 
minute and finally ending with 1 cycle of 72°C for 5 minutes; reactions performed 
by Stratagene Mx4000 Multiplex Quantitative PCR System and corresponding 
software Mx4000 version 4.20. 
 
qPCR Data Analysis and Statistics 
All qPCR tubes prepared in triplicate, and mRNA levels normalized to 
constitutively active genes glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) in murine cells or 40S ribosomal protein S18 (RPS18) in human cells. 
Expression of target mRNA (Egr1) set equal to 1.0 in non-stimulated (baseline) 
cells, and expression of target mRNA quantified as fold-increase above baseline 
in insulin-, humulin-, or ACEA-stimulated cells. Triplicate results averaged and 
bars represent standard deviation. Significance of difference in mRNA 
expression levels assessed using student’s t-test.  
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RESULTS 
 
 Because of recent discoveries by the Kandror Lab that mTORC1 induces 
Egr1 expression, and that Egr1 binds the ATGL promoter and decreases ATGL 
expression, we investigated the effect of CB1 stimulation on Egr1 and ATGL 
expression. To stimulate CB1, we used ACEA, a synthetic analogue of 
endocannabinoid AEA. 
 In murine 3T3-L1 adipocytes, stimulation with 2 uM ACEA for 4 hours 
induced a 4.8-fold increase in Egr1 mRNA relative to control adipocytes receiving 
no ACEA (Figure 8), as determined by qPCR. All qPCR reactions were 
performed in triplicate, and mRNA levels were normalized to GAPDH mRNA. 
This mRNA expression change was statistically significant (p<0.01) as assessed 
by the student’s t-test. 
 Total protein was also collected from 3T3-L1 adipocytes having 
undergone identical conditions, and levels of ATGL and Egr1 protein were 
assessed by Western blot. After 4 hours of CB1 stimulation with 2 uM ACEA or 
no ACEA, there was no appreciable difference in ATGL or Egr1 protein levels 
(Figure 9). GAPDH protein was blotted as a loading control. 
 The experiment was repeated in cultured human adipocytes. A third 
condition was tested in these cells: 4 hour stimulation with 100 nM humulin. In 
these human adipocytes, 4 hour stimulation with 100 nM humulin increased Egr1 
mRNA by a factor of 2.6 relative to control cells receiving no stimulation. 
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Moreover, 4 hour stimulation with 2 uM ACEA increased Egr1 mRNA by a factor 
of 5.1 relative to control cells receiving no stimulation (Figure 10). Both of these 
mRNA expression changes were statistically significant (p<0.05) as assessed by 
the student’s t-test. All qPCR reactions were performed in triplicate, and mRNA 
levels were normalized to RPS18 mRNA. 
 A separate trial was conducted where human adipocytes received either 4 
hour or 16 hour CB1 stimulation with 2 uM ACEA. Total protein was collected 
and levels of ATGL were assessed by Western blot. At both time points, ATGL 
protein was increased relative to cells receiving no ACEA (Figure 11). GAPDH 
protein was blotted as a loading control. We also blotted for Egr1 protein, but the 
gel produced an unreadable blot.  
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Figure 8. ACEA induces Egr1 in murine 3T3-L1 adipocytes. On day 6 of 3T3-
L1 adipocyte differentiaton, cells were serum-starved for 3 hours followed by 
stimulation with 2uM ACEA or no stimulation. After 4 hours, RNA was harvested 
and reverse transcribed to cDNA. qPCR samples were prepared in triplicate, and 
the bar represents standard deviation. mRNA levels were normalized to GAPDH 
mRNA levels. **p<0.01. Egr1 – early growth responsive gene 1; ACEA – 
arachidonyl-2’-chloroethylamide; CB1 – cannabinoid receptor 1; GAPDH – 
glyceraldehyde 3-phosphate dehydrogenase.  
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Figure 9. ACEA does not affect Egr1 or ATGL protein. On day 6 of 3T3-L1 
adipocyte differentiaton, cells were serum-starved for 3 hours followed by 
stimulation with 2uM ACEA or no stimulation. After 4 hours, cell lysate was 
harvested. GAPDH served as loading control. ATGL – adipose triglyceride lipase; 
Egr1 – early growth responsive gene 1; ACEA – arachidonyl-2’-chloroethylamide; 
CB1 – cannabinoid receptor 1; GAPDH – glyceraldehyde 3-phosphate 
dehydrogenase. 
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Figure 10. Insulin and ACEA induce Egr1 in human adipocytes. On day 13 of 
human adipocyte differentiaton, cells were dexamethasone- and insulin-starved 
for 3 hours followed by stimulation with 100nM humulin or 2uM ACEA or no 
stimulation. After 4 hours, RNA was harvested and reverse transcribed to cDNA. 
qPCR samples were prepared in triplicate, and the bars represent standard 
deviation. mRNA levels were normalized to RPS18 mRNA levels. *p<0.05. Egr1 
– early growth responsive gene 1; ACEA – arachidonyl-2’-chloroethylamide; CB1 
– cannabinoid receptor 1; RPS18 – 40S ribosomal protein S18. 
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Figure 11. ACEA increases ATGL protein in human adipocytes. On day 13 of 
human adipocyte differentiaton, cells were dexamethasone- and insulin-starved 
for 3 hours followed by stimulation with 2uM ACEA or no stimulation. After 0, 4, 
and 16 hours, cell lysate was harvested. GAPDH served as loading control. 
ATGL – adipose triglyceride lipase; ACEA – arachidonyl-2’-chloroethylamide; 
CB1 – cannabinoid receptor 1; GAPDH – glyceraldehyde 3-phosphate 
dehydrogenase. 
 
 
 
 
DISCUSSION 
 
 Several recent discoveries led us to test the effect of CB1 stimulation on 
Egr1 and ATGL expression in adipocytes. ATGL, the rate-limiting lipolytic 
enzyme in adipose tissue, is downregulated in the insulin-stimulated state, and 
this antilipolytic signal is defective in obesity and T2DM and may contribute to 
lipotoxicity [24]. The antilipolytic effect of insulin on AT is mediated by mTORC1 
[36]. Recently, the Kandror Lab identified the transcription factor Egr1 as the 
 41 
mediator between activated mTORC1 and decreased ATGL transcription 
(unpublished data). Activated mTORC1 increases the expression of Egr1 mRNA 
and protein, and Egr1 binds the ATGL promoter and decreases transcription of 
ATGL. This is an evolutionarily conserved interaction and is documented in 
yeast, fruit fly, and mice (unpublished data). 
 Egr1 has recently been implicated in several new models of the 
pathogenesis of adipose tissue insulin resistance in the pre-diabetic 
hyperinsulinemic state [37] [49]. These authors assert that chronic 
hyperinsulinism causes an imbalance between PI3K/Akt signaling and MAPK 
signaling. Specifically, high levels of Egr1 in obesity and diabetes increase MAPK 
signaling via increased Ras prenylation, an effect of Egr1 transactivation of the 
GGPPS gene. Concurrently, Egr1 transactivates the PTEN gene, an inhibitor of 
PI3K/Akt signaling. Overactive ERK (MAPK) phosphorylates and inactivates 
IRS1, which also diminishes PI3K/Akt signaling. Diminished PI3K/Akt signaling 
decreases insulin-stimulated GLUT4 translocation to the cell surface and 
decreases plasma glucose clearance in the fed state. 
 The endocannabinoid system (ECS) is known to be overactive in obesity 
and diabetes [52], and CB1 antagonism by the drug rimonabant was effective at 
decreasing weight and improving insulin resistance in overweight and obese 
patients [56]. It is conceivable that overactive ECS in obesity could contribute to 
the development of insulin resistance, and we sought to determine the effects of 
CB1 stimulation on Egr1 expression. Previous research demonstrated induction 
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of Egr1 by CB1 stimulation in neurons [57] [53], however the induction of Egr1 by 
CB1 stimulation has not been demonstrated in adipocytes. 
 By using quantitative PCR, we were able to assess the change in Egr1 
mRNA levels in CB1-stimulated murine 3T3-L1 adipocytes and human 
adipocytes relative to non-stimulated control adipocytes. In both cell types, 
stimulation with 2 uM ACEA (a synthetic analogue of endocannabinoid AEA and 
a specific CB1 agonist) significantly induced Egr1 mRNA after 4 hours (Figures 8 
and 10). Stimulation of human adipocytes with 100 nM humulin also significantly 
induced Egr1 mRNA, although to a lesser extent than did ACEA. 
 Western blot analysis showed no change in Egr1 or ATGL protein levels 
after 4 hours of ACEA stimulation in murine 3T3-L1 adipocytes (Figure 9). This 
result corresponds to previous data from the Kandror Lab showing no increase in 
Egr1 protein until 8 hours of insulin stimulation, and no decrease in ATGL protein 
until 16 hours of insulin stimulation. Figure 9 is in agreement with the finding that 
Egr1 mRNA increase precedes Egr1 protein increase by hours, and Egr1 protein 
increase precedes ATGL mRNA and protein decrease by hours (unpublished 
Kandror data). 
 The one surprising result was the increase of ATGL protein in 4-hour and 
16-hour ACEA stimulated human adipocytes (Figure 11). This result runs counter 
to the previous finding that increasing Egr1 mRNA leads to decreased ATGL 
expression. A closer examination of the components of the human adipocyte 
media (which was kindly donated by Mi-Jeong Lee, PhD, of the Fried Laboratory 
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and was much more complex than our typical murine 3T3-L1 media) is 
necessary to assess for confounding factors. Unfortunately, the Egr1 blot was 
unreadable due to gel abnormalities. The experiment requires repeating.  
 A necessary future experiment would be a time course similar to the one 
described in the unpublished Kandror data. Egr1 and ATGL mRNA and protein 
should be measured at 4-, 8-, and 16-hour ACEA stimulation. It is logical that the 
results of that future experiment would mirror the results of the insulin time 
course described in the Introduction section. A second future experiment worth 
performing is a similar time course experiment and measurement of Egr1 and 
ATGL mRNA and protein, except using CB1 antagonist SR141716A 
(rimonabant). Logically, the result should be reversed: Egr1 expression should 
decrease, followed by an ATGL increase.  
 Future investigation is also necessary to dissect the pathways through 
which CB1 stimulation induces Egr1. CB1 activates the MAPK pathway [54], but 
is ERK the dominant stimulator of Egr1 expression, or is mTORC1 the major 
mediator? (ERK induces Egr1 directly and also activates mTORC1, and 
mTORC1 induces Egr1 independently of ERK.) Furthermore, elucidation of CB1 
signal transduction in adipocytes is crucial for the future development of 
peripheral-specific drugs that bind CB1. The major downfall of the otherwise 
highly effective rimonabant was the adverse psychiatric effects, which would be 
attenuated by cannabinoid drugs designed for brain exclusion.  
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 Finally, the sequence of events in obesity and T2DM disease progression 
remains somewhat perplexing. Some of the research findings are counter-
intuitive and portend even greater complexity than is currently understood. For 
example, insulin resistant adipose tissue has defective antilipolytic signal, yet 
ATGL expression is decreased in obese and diabetic patients and ob/ob and 
db/db mice [22]. Decreased ATGL expression in these disease states would be 
expected to decrease plasma FFA and lipotoxicity, but the opposite is true. 
These and other seemingly contradictory findings will continue to fuel research in 
the “diabesity” epidemic for quite awhile.  
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